Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.France-based provider of allogeneic CAR T-cell therapies, Cellectis has signed a strategic collaboration agreement with French pharmaceutical research company Servier to develop and commercialize new product candidates targeting leukemia and solid tumors.
Subscribe to our email newsletter
The deal covers the development and potentially the commercialization of Cellectis’ lead product candidate, UCART19, as well as the research, development, and commercialization of five other product candidates targeting solid tumors .
As part of the deal, Cellectis will be responsible for the research and development (R&D) of certain product candidates through the end of Phase I.
While Servier might exercise an exclusive worldwide option for a license on each product candidate developed under the deal.
After exercising each option, the company will be responsible for taking over clinical development, registration and commercialization of each product.
Financial terms of the deal include an upfront payment of $10m and up to $140m for each of the six product candidates potentially developed, spread over several milestones in the development and commercialization phases.
Additionally, Cellectis will receive royalties on the sales of commercialized products.
Servier head of the Oncology Innovation Center Jean-Pierre Abastado said, "These original cell-based therapies will well complement Servier’s innovative clinical oncology pipeline, which currently includes immunotherapeutic monoclonal antibodies, an HDAC inhibitor, kinase inhibitors, antiangiogenic and proapoptotic small molecules."